Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 65-71

  Perju Dumbrava, Laura D ^a,b   Kovacs, Gabor G ^a   Pirker, Susanne ^c   Jellinger, Kurt ^d   Hoffmann, Martha ^b   Asenbaum, Susanne ^b   Pirker, Walter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Dopamine transporter; Dopaminergic degeneration; Multiple system atrophy; Parkinson's disease; Single photon emission computerized tomography

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RETROSPECTIVE STUDY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; AUTOPSY; CEREBELLUM; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84855950928     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24000     Document Type: Article

References (37)

1. Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994; 14: 982-994.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318: 876-880.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114: 2283-2301.
4. Counihan TJ, Penney JB Jr. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. J Neurol Neurosurg Psychiatry. 1998; 65: 164-169.
5. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain. 1990; 113: 1823-1842.
6. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001; 16: 1023-1032.
7. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004; 31: 1631-1638.
8. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992; 42: 1142-1146.
9. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001; 57: 1497-1499.
10. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995; 58: 160-166.
11. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996; 55: 97-105.
12. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
13. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999; 163: 94-98.
14. Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2010; 29: 271-288.
15. Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000; 15: 1158-1167.
16. Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000; 41: 36-44.
17. Perju-Dumbrava L, Kovacs GG, Jellinger K, et al. DAT SPECT in post mortem-confirmed parkinsonian disorders. Eur J Neurol. 2009; 16( Suppl 3): 519.
18. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001; 56: 730-736.
19. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004; 19: 1043-1049.
20. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994; 117: 835-845.
21. Colosimo C, Albanese A, Hughes AJ, de Bruin VM, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol. 1995; 52: 294-298.
22. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997; 54: 937-944.
23. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002; 125: 861-870.
24. Litvan I, Agid Y, Goetz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997; 48: 119-125.
25. Ling H, O'sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010; 133: 2045-2057.
26. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-676.
27. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000; 68: 434-440.
28. Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010; 133: 2382-2393.
29. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995; 38: 589-598.
30. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997; 50: 9-24.
31. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002; 17: 303-312.
32. Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. 2005; 128: 1605-1612.
33. El Fakhri G, Habert MO, Maksud P, et al. Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2006; 33: 87-92.
34. Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004; 45: 49-55.
35. Zijlmans J, Evans A, Fontes F, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord. 2007; 22: 1278-1285.
36. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med. 2001; 42: 408-413.
37. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002; 17: 518-523.